Related Experiment Video

Updated: Mar 8, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.3K

FGFR-targeted therapeutics for the treatment of breast cancer

Antonella De Luca1, Daniela Frezzetti1, Marianna Gallo1

  • 1a Cell Biology and Biotherapy Unit , Istituto Nazionale Tumori 'Fondazione G. Pascale'-IRCCS , Naples , Italy.

Expert Opinion on Investigational Drugs
|January 26, 2017
PubMed
Abstract

Insights

Fibroblast growth factor receptor (FGFR) inhibitors show promise for breast cancer but early trials yielded disappointing results. Future research should focus on biomarkers and combination strategies to improve efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer progression is influenced by molecular drivers, including deregulated Fibroblast Growth Factor Receptor (FGFR) signaling.
  • The FGFR/FGF axis plays a role in tumor pathogenesis, making FGFR-targeted agents a potential therapeutic strategy.
  • FGFR inhibitors are being investigated for various cancer types, including breast cancer.

Purpose of the Study:

  • To review targeted agents against FGFRs and their clinical development in breast cancer.
  • To discuss the latest literature and clinical trial data regarding FGFR inhibitors in breast cancer.
  • To provide expert opinion on the current status and future directions of FGFR-targeted therapies.

Main Methods:

  • Comprehensive literature search for relevant studies on FGFR inhibitors in breast cancer.
  • Analysis of data from the Clinicaltrials.com database.
  • Synthesis of findings to provide an overview of targeted agents and clinical development.

Main Results:

  • FGFR inhibition is a promising therapeutic approach for several tumor types.
  • Preliminary clinical trial results for FGFR inhibitors in breast cancer have been disappointing.
  • Further research is needed to understand FGFR aberrations and identify predictive biomarkers.

Conclusions:

  • Optimizing FGFR-targeted therapies in breast cancer requires a deeper understanding of FGFR aberrations.
  • Biomarker identification is crucial for selecting patients who will benefit from FGFR inhibitors.
  • Developing strategies to enhance efficacy and minimize toxicity is essential for successful FGFR-targeted treatment in breast cancer.
Keywords:
FGFR genetic alterationsFGFR-targeted agentsFibroblast growth factor receptorbreast cancer

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57